How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,039 results for

Oxcarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Oxcarbazepine

Oxcarbazepine Top results for oxcarbazepine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for oxcarbazepine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine Clinical Pharmacogenetics Implementation Consortium Guideline forHLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update ElizabethJ.Phillips 1 ,ChonlaphatSukasem 2,3 ,MichelleWhirl-Carrillo 4 ,DanielJ.M€ uller 5,6 , HenryM.Dunnenberger 7 ,WasunChantratita 8,9 ,BarryGoldspiel 10 ,Yuan-TsongChen 11,12 , BruceC.Carleton 13 ,AlfredL.GeorgeJr. 14 (...) supporting these associations and provide recommendationsforcarbamazepineandoxcarbazepineusebased onHLAgenotypes. Human leukocyte antigen (HLA) genetic variation is implicated in the development of speci?c cutaneous adverse reactions to aro- matic anticonvulsants. The purpose of this guideline is to inter- pret HLA-B*15:02 and HLA-A*31:01 genotyping results to guide the use of carbamazepine and oxcarbazepine. Detailed guidelines regarding the selection of alternative therapies, when to conduct genotype

2017 Clinical Pharmacogenetics Implementation Consortium

3. WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. Full Text available with Trip Pro

WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the effects of oxcarbazepine when used as an add (...) -on treatment for drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group's Specialized Register (28 March 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (1966 to March 2006). No language restrictions were imposed. We checked the reference lists of retrieved studies for additional reports of relevant studies. We also contacted Novartis (manufacturers of oxcarbazepine) and experts in the field.Randomized, placebo-controlled

2016 Cochrane

4. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms. Full Text available with Trip Pro

Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms. Genetic polymorphisms are related to the concentration and efficacy of oxcarbazepine (OXC). 10-Hydroxycarbazepine (MHD) is the major pharmacologically active metabolite of OXC, and it exerts an antiepileptic effect. This study aimed to explore the connection between the MHD concentration and genes such as ATP-binding cassette B1 (ABCB1), ATP

2019 Medicine

5. Changes in background electroencephalographic activity in benign childhood epilepsy with centrotemporal spikes after oxcarbazepine treatment: a standardized low-resolution brain electromagnetic tomography (sLORETA) study. Full Text available with Trip Pro

Changes in background electroencephalographic activity in benign childhood epilepsy with centrotemporal spikes after oxcarbazepine treatment: a standardized low-resolution brain electromagnetic tomography (sLORETA) study. Several neuroimaging studies have reported neurophysiological alterations in patients with benign childhood epilepsy with centrotemporal spikes (BCECTS). However, reported outcomes have been inconsistent, and the progression of these changes in the brain remains unresolved (...) . Moreover, background electroencephalography (EEG) in cases of BCECTS has not been performed often.We investigated background EEG activity changes after six months of oxcarbazepine treatment to better understand the neurophysiological alterations and progression that occur in BCECTS. In 18 children with BCECTS, non-parametric statistical analyses using standardized low resolution brain electromagnetic tomography (sLORETA) were performed to compare the current density distribution of four frequency bands

2019 BMC Neurology

6. Oxcarbazepine versus Other Anticonvulsants for the Treatment of Epilepsy: Clinical Effectiveness and Safety

Oxcarbazepine versus Other Anticonvulsants for the Treatment of Epilepsy: Clinical Effectiveness and Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Oxcarbazepine versus

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Oxcarbazepine for Non-Epilepsy Indications: Clinical Effectiveness and Safety

Oxcarbazepine for Non-Epilepsy Indications: Clinical Effectiveness and Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Oxcarbazepine for Non-Epilepsy Indications

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: A randomized controlled trial. (Abstract)

Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: A randomized controlled trial. Neuron-specific enolase (NSE) is the most investigated biomarker in the context of epilepsy and brain damage. The present study was conducted to investigate the change in serum NSE in patients with focal seizure and the effect of carbamazepine and oxcarbazepine on serum NSE. The present study is a randomized, open-label, parallel design clinical trial (ClinicalTrials.gov (...) Identifier: NCT02705768) conducted on 60 patients of focal seizure. After recruitment, detailed history, clinical evaluations including Chalfont-National Hospital seizure severity scale (NHS3), Quality of Life in Epilepsy Inventory (QOLIE-31) and serum NSE estimation were done at baseline. Thirty healthy volunteers were recruited for a baseline evaluation of serum NSE. After randomization, one group received tablet oxcarbazepine and another group received tablet carbamazepine. At 4 weeks follow-up, all

2018 Epilepsy research Controlled trial quality: uncertain

9. A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

10. Randomized trial of betahistine mesilate tablets as augmentation for oxcarbazepine and carbamazepine in treating vestibular paroxysmia Full Text available with Trip Pro

Randomized trial of betahistine mesilate tablets as augmentation for oxcarbazepine and carbamazepine in treating vestibular paroxysmia Vestibular paroxysmia (VP) is a rare episodic peripheral vestibular disorder. This study was conducted to compare the efficacy and acceptability of carbamazepine (CBZ) plus betahistine mesilate tablets (BMT) (CBZ+BMT) and oxcarbazepine (OXC) plus BMT (OXC+BMT) in treating VP, and investigated whether the synergistic effect could be increased along

2018 Drug design, development and therapy Controlled trial quality: uncertain

11. Reversible splenial lesion syndrome due to oxcarbazepine withdrawal: case report and literature review Full Text available with Trip Pro

Reversible splenial lesion syndrome due to oxcarbazepine withdrawal: case report and literature review Background Reversible splenial lesion syndrome is a distinct entity radiologically characterized by a reversible lesion in the splenium of the corpus callosum. According to previous reports, this condition may be associated with antiepileptic drug use or withdrawal. We herein report a case of reversible splenial lesion syndrome associated with oxcarbazepine withdrawal. Case Report A 39-year (...) -old man presented with an 8-year history of epileptic seizures. During the previous 3 years, he had taken oxcarbazepine irregularly. One week prior to admission, he withdrew the oxcarbazepine on his own, and the epilepsy became aggravated. Magnetic resonance imaging (MRI) revealed an isolated lesion in the splenium of the corpus callosum with slight hypointensity on T1-weighted imaging and slight hyperintensity on T2-weighted imaging. Regular oxcarbazepine was prescribed. Over a 5-month follow-up

2018 The Journal of international medical research

12. Expression of Multidrug Resistance Genes in Peripheral Blood of Patients with Refractory Epilepsy and the Reverse Effect of Oxcarbazepine on Its Expression Full Text available with Trip Pro

Expression of Multidrug Resistance Genes in Peripheral Blood of Patients with Refractory Epilepsy and the Reverse Effect of Oxcarbazepine on Its Expression We aimed to investigate the expression levels of multidrug resistance gene 1 (MDR1), multidrug resistance-associated protein 1 (MRP1) and multidrug resistance P-glycoprotein (P-gp) in peripheral blood of patients with refractory epilepsy.Patients with epilepsy (n=24) and those with refractory epilepsy (n=24) were selected, and 30 normal (...) volunteers were enrolled as control. The expression level of MDR1 genes was detected using semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR). The expression levels of P-gp and MRP1 were detected via Western blotting. The above-mentioned patients with refractory epilepsy were randomly divided into the oxcarbazepine group (OB group) and placebo group (OZ group). After consecutive 8-week oral administration of drugs, the curative effect and adverse reactions of patients

2018 Iranian journal of public health Controlled trial quality: uncertain

13. Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: a back-translational study of oxcarbazepine. Full Text available with Trip Pro

Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: a back-translational study of oxcarbazepine. The term 'irritable nociceptor' was coined to describe neuropathic patients characterized by evoked hypersensitivity and preservation of primary afferent fibres. Oxcarbazepine is largely ineffectual in an overall patient population, but has clear efficacy in a subgroup with the irritable nociceptor profile. We examine whether neuropathy in rats induced (...) . The former measure was in part dependent on ongoing peripheral activity as intraplantar lidocaine also reduced aberrant spontaneous thalamic firing. Systemic oxcarbazepine had no effect on wind-up of dorsal horn neurones in sham and SNL rats. However, in SNL rats, oxcarbazepine markedly inhibited punctate mechanical-, dynamic brush- and cold-evoked neuronal responses in the VPL and dorsal horn, with minimal effects on heat-evoked responses. In addition, oxcarbazepine inhibited spontaneous activity

2018 European Journal of Pain

14. Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control. Full Text available with Trip Pro

Hepatitis C-related cryoglobulinemic neuropathy: potential role of oxcarbazepine for pain control. Peripheral neuropathy is one most common, limiting and invalidating neurological symptom in subjects with hepatitis C virus and mixed cryoglobulinemia. Notably, the medical therapy proposed to eradicate HCV, can frequently exacerbate the painful neuropathy. Therefore, neuropathy therapies are insufficient and inadequate, and comprise immunosuppressive drugs, such as steroid or cyclosporine (...) , intravenous immunoglobulin or plasma exchange. These have shown variable success in case reports, with a presumably temporary effect, but with major side effects.We assessed the effects of oxcarbazepine treatment in 67 cases of cryoglobulinemia related neuropathy, who did not respond to either steroid or Gabapentin, or Pregabalin. Oxcarbazepine was chosen based on the promising preliminary results.Patients treated with Oxcarbazepine showed a rapid, discrete and persistent relief of polyneuropathic signs

2018 BMC Gastroenterology

15. <i>HLA-A*31:01</i> and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete <i>DCX</i> Deletion. Full Text available with Trip Pro

HLA-A*31:01 and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete DCX Deletion. Oxcarbazepine is an antiepileptic drug (AED) commonly used as a first-line treatment option for focal epilepsy. Several AEDs, including carbamazepine, oxcarbazepine, and phenytoin are associated with various delayed-hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, or toxic epidermal necrolysis. The Food and Drug (...) Administration-approved label for oxcarbazepine currently presents information regarding a pharmacogenomic association with the HLA antigen allele HLA-B*15:02 and hypersensitivity reactions in certain ancestry groups with a high incidence of this allele. However, unlike carbamazepine, screening for the presence of this allele is not routinely recommended before administration of oxcarbazepine. In practice, even with carbamazepine, HLA antigen testing is not always performed before initiating treatment

2018 Pediatrics

16. Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression

Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03567681 Recruitment Status : Enrolling by invitation First Posted : June 25, 2018 Last Update Posted : June 25, 2018 Sponsor: Collaborative Care Initiative, LLC

2018 Clinical Trials

17. Oxcarbazepine Therapy for Complete Central Diabetes Insipidus Full Text available with Trip Pro

Oxcarbazepine Therapy for Complete Central Diabetes Insipidus Oxcarbazepine and carbamazepine cause hyponatremia by unknown mechanisms. We describe a patient with complete central diabetes insipidus and seizures who developed worsening hyponatremia when her dose of oxcarbazepine was increased. The patient maintained a normal serum sodium level and has had appropriately concentrated urine for 5 years on just oxcarbazepine, despite undetectable antidiuretic hormone (ADH) levels. This suggests (...) that oxcarbazepine (or one of its metabolites) may stimulate collecting tubule V2 receptor-G protein complex independent of ADH, resulting in increased renal tubular water reabsorption. Oxcarbazepine may be useful as an alternative therapy for patients with central diabetes insipidus.

2018 Case Reports in Nephrology and Dialysis

18. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Full Text available with Trip Pro

The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. To investigate the effects of antiepileptic drugs (AEDs; oxcarbazepine [OXC], levetiracetam [LEV], and lamotrigine [LTG]) on semen quality, sexual function, and sex hormones in male adults with epilepsy.Individual treatment with OXC, LEV, or LTG was randomly assigned to 38 newly diagnosed male adult patients with epilepsy. Semen quality and sex hormones

2018 Epilepsia Controlled trial quality: uncertain

19. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. (Abstract)

Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Oxcarbazepine is indicated for the treatment of partial or generalised tonic-clonic seizures. Most of the absorbed oxcarbazepine is converted into its active metabolite, 10-hydroxycarbazepine (MHD), which can exist as R-(-)- and S-(+)-MHD enantiomers. Here we describe the influence of the P-glycoprotein (P-gp) inhibitor verapamil, on the disposition of oxcarbazepine and MHD enantiomers (...) , both of which are P-gp substrates. Healthy subjects (n=12) were randomised to oxcarbazepine or oxcarbazepine combined with verapamil at doses of 300mg b.i.d. and 80mg t.i.d., respectively. Blood samples (n=185) were collected over a period of 12h post oxcarbazepine dose. An integrated PK model was developed using nonlinear mixed effects modelling using a meta-analytical approach. The pharmacokinetics of oxcarbazepine was described by a two-compartment model with absorption transit compartments

2018 European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences Controlled trial quality: uncertain

20. Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions Risk of serious skin-related adverse drug reactions, including Stevens-Johnson syndrome, occurring with carbamazepine may be increased in the presence of the HLA (...) -A*3101 allele in patients of European descent or Japanese origin. Published 11 December 2014 From: Therapeutic area: , Article date: December 2012 Carbamazepine (Tegretol) is an antiepileptic drug that is indicated for the treatment of generalised tonic clonic seizures. Carbamazepine is also licensed to treat the paroxysmal pain of trigeminal neuralgia and for the prophylaxis of manic-depressive psychosis in patients unresponsive to lithium therapy. Oxcarbazepine (Trileptal) is indicated

2012 MHRA Drug Safety Update

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>